MHRA approves icotrokinra hydrochloride for moderate to severe plaque psoriasis
Start here
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved icotrokinra hydrochloride, brand name Icotyde, on 23 October 2026 as an oral treatment for moderate to severe plaque psoriasis. The approval covers patients aged 12 years and older who weigh at least 40 kg. Icotrokinra is taken by mouth, distinguishing it from injected biologics commonly used for this disease. The approval marks the drug's entry into the UK market; questions such as uptake, pricing and comparative performance against existing therapies remain open.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- gov.ukPickMHRA approves new oral treatment for moderate to severe plaque psoriasis
The UK MHRA approved icotrokinra hydrochloride (Icotyde) on 23 October 2026 for patients aged 12 years and older weighing at least 40 kg with moderate to severe plaque psoriasis.
Heat trend for this story
Heat now 6·Peak in the comparable set 10 (Oct 23 21:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.